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ARTICLE
Downregulation of macrophage Irs2 by
hyperinsulinemia impairs IL-4-indeuced M2a-
subtype macrophage activation in obesity
Tetsuya Kubota1,2,3,4,5, Mariko Inoue1,3, Naoto Kubota1,2,3,6, Iseki Takamoto1,
Tomoka Mineyama1, Kaito Iwayama7, Kumpei Tokuyama7, Masao Moroi4, Kohjiro Ueki1,
Toshimasa Yamauchi 1 & Takashi Kadowaki 1,8,9
M2a-subtype macrophage activation is known to be impaired in obesity, although the
underlying mechanisms remain poorly understood. Herein, we demonstrate that, the IL-4/
Irs2/Akt pathway is selectively impaired, along with decreased macrophage Irs2 expression,
although IL-4/STAT6 pathway is maintained. Indeed, myeloid cell-speciﬁc Irs2-deﬁcient mice
show impairment of IL-4-induced M2a-subtype macrophage activation, as a result of stabi-
lization of the FoxO1/HDAC3/NCoR1 corepressor complex, resulting in insulin resistance
under the HF diet condition. Moreover, the reduction of macrophage Irs2 expression is
mediated by hyperinsulinemia via the insulin receptor (IR). In myeloid cell-speciﬁc IR-deﬁ-
cient mice, the IL-4/Irs2 pathway is preserved in the macrophages, which results in a reduced
degree of insulin resistance, because of the lack of IR-mediated downregulation of Irs2. We
conclude that downregulation of Irs2 in macrophages caused by hyperinsulinemia is
responsible for systemic insulin resistance via impairment of M2a-subtype macrophage
activation in obesity.
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Obesity is known to cause chronic low-grade inﬂammation,resulting in insulin resistance and type 2 diabetes1,2.Chronic low-grade inﬂammation is recognized as being
caused by adipose tissue macrophage (ATM) accumulation,
which has been shown to increase with body weight gain in both
humans and rodents3–8. Thus, macrophages (MΦs) per se are, at
least in part, responsible for the insulin resistance observed in
obesity. MΦs can be divided into two major populations; the M1-
type MΦs, representing the classically activated MΦs, which are
activated by Th1 cytokines to generate proinﬂammatory cyto-
kines, and the M2-type MΦs, representing the alternatively
activated MΦs, which are activated by Th2 cytokines to generate
anti-inﬂammatory cytokines9. ATMs from lean mice showed high
expression levels of the M2-type MΦ marker genes. These
expressions were found to be decreased under the high-fat (HF)
diet condition10, associated with aggravation of the insulin
resistance11,12. M2-type MΦs are classiﬁed at least in three sub-
populations, M2a-subtype, M2b-subtype and M2c-subtype, based
upon the inducing agent and molecular marker expression. M2a-
subtype MΦs activated by IL-4 or IL-13 promote of Th2-type
inﬂammation against enhanced ﬁbrosis and wound healing by
increased arginase1(Arg1), FIZZ1 (also called Retnla) and Ym1
(also called Chi3l3) expression levels. M2b-subtype MΦs are
induced by combined exposure to immune complexes with Toll-
like receptor (TLR)- or IL-1 receptor (IL1R)-ligands, whereas
M2c-subtype MΦs are induced by IL-10. M2b-subtype MΦs with
concomitant high IL-10 and low IL-12 suppress inﬂammatory
cytokines and molecules involving in lymphocytic activation.
M2c-subtype MΦs are thought to be predominantly responsible
for negative/deactivating immunoregulation13,14.
In the adipose tissue, eosinophils are recognized as a source of
IL-4 production, and eosinophil-deﬁcient mice showed insulin
resistance and impaired glucose tolerance under the HF diet
condition, with a decrease of IL-4 production and number of
M2a-subtype MΦs15. Decreased M2a-subtype MΦ activation by
IL-4 renders mice susceptible to diet-induced obesity and glucose
intolerance16. These data suggest that M2a-subtype MΦ activa-
tion by IL-4 is impaired in obesity, resulting in obesity-induced
insulin resistance.
IL-4 binds to two types of receptors; the type I receptor, which
is composed of IL-4 receptor (IL-4R)α and the common γ chain
(γC), and the type II receptor, which is composed of IL-4Rα and
IL-13 receptor (IL-13R)α117. IL-4Rα binds janus kinases (JAK)1,
which is crucial for the phosphorylation of signal transducer and
activator of transcription 6 (STAT6). IL-4-induced STAT6
phosphorylation was necessary for M2a-subtype MΦ activation.
In fact, M2a-subtype MΦ activation by IL-4 was impaired in
systemic STAT6-deﬁcient mice and myeloid cell-speciﬁc IL-4Rα-
deﬁcient mice16,18,19. In addition to STAT6, Irs2, which was
previously called IL-4-induced phosphotyrosine (4PS)20, is also
activated and phosphorylated by IL-4 via the γC in macrophages.
IL-4-induced Irs2 phosphorylation and M2a-subtype macrophage
activation were decreased in γC-deﬁcient macrophages21. How-
ever, the underlying mechanisms by which M2a-subtype mac-
rophage activation by IL-4 was impaired in obesity remain poorly
understood. To clarify whether Irs2 is involved in impaired IL-4-
induced M2a-subtype macrophage activation, we analyzed mye-
loid cell-speciﬁc Irs2-deﬁcient (MIrs2KO) mice under the high-fat
(HF) diet condition, and attempted to determine the signaling
mechanisms by which IL-4/Irs2 pathway would regulate M2a-
subtype macrophage activation.
Results
MIrs2KO mice exhibited insulin resistance and inﬂammation.
To investigate the IL-4 signaling in MΦs in obesity, peritoneal
MΦs were collected from normal chow (NC) and HF diet-fed
mice after thioglycollate injection. The phosphorylation levels of
STAT6 induced by IL-4 in the peritoneal MΦs did not differ
between the NC and HF diet-fed mice (Fig. 1a). In contrast, the
phosphorylation levels of Irs2 induced by IL-4 were signiﬁcantly
reduced along with decreased MΦ Irs2 expression in the HF diet-
fed mice (Fig. 1a and Supplementary Fig. 1a). SiglecF-CD11b+F4/
80+ cells of the stromal vascular fraction (SVF) of the white
adipose tissue (WAT) were collected from mice with genetically
(ob/ob) or environmentally induced (15-week, HF diet-fed)
obesity (Supplementary Fig. 1b). While there were no signiﬁcant
differences in the expression levels of IR, IL-4R or STAT6 between
the two mouse models of obesity (Supplementary Fig. 1b, c), the
expression levels of Irs2 mRNA were signiﬁcantly reduced in both
(Fig. 1b, c). Expression of Irs1 mRNA was undetectable in these
cells, as previously reported (Supplementary Fig. 1c, d)22. Since it
has been shown that the M1- and M2-type MΦ fractions are
clearly separable using CD11c and CD206, the classic markers of
M1- and M2-type MΦs, respectively23, we investigated the
expression levels of Irs2 in siglecF-CD11b+F4/80+CD11c+ cells
(M1-type MΦs) and siglecF-CD11b+F4/80+CD206+ cells (M2-
type MΦs) in the SVCs of the adipose tissue derived from NC and
HF diet-fed mice. The expression levels of Irs2 mRNA were sig-
niﬁcantly reduced in both the types of cells derived from HF diet-
fed mice (Supplementary Fig. 1e). These data suggest that IL-4/
Irs2-mediated signaling in the MΦs is impaired in obesity.
To investigate the role of Irs2 in the MΦs, we then generated
MIrs2KO mice. Although there were no signiﬁcant differences in
the mRNA expression levels of IR or IL-4R in the bone marrow-
derived MΦs (BMDM) between the control and MIrs2KO mice,
the Irs2 mRNA and protein expressions were almost completely
abrogated in the BMDM of the MIrs2KO mice (Supplementary
Fig. 2a, b). Furthermore, Irs1 mRNA expression was undetectable
in the BMDM of both the control and MIrs2KO mice
(Supplementary Fig. 2a). There were no signiﬁcant differences
in the body weight (BW), results of the insulin tolerance test
(ITT) and oral glucose tolerance test (OGTT) or the lipid proﬁles
between the two models of mice under the NC diet condition
(Supplementary Fig. 2c-f). We analyzed the percentages of the
siglecF-CD11b+F4/80+ cells, siglecF-CD11b+F4/80+CD11c+
cells and siglecF-CD11b+F4/80+CD206+ cells in the SVF of the
adipose tissue derived from the NC-fed MIrs2KO mice. There
were no differences in the percentages of any of these cells
between the control and MIrs2KO mice under the NC diet
condition (Supplementary Fig. 2g). Under HF diet condition,
however, the blood glucose and plasma insulin levels during the
OGTT were signiﬁcantly higher in the MIrs2KO mice, although
there were no signiﬁcant differences in the BW gain, lean body
mass or percent body fat (%FAT) between the control and
MIrs2KO mice (Fig. 1d and Supplementary Fig. 3a, b). In the
hyperinsulinemic-euglycemic clamp study, the MIrs2KO mice
showed a reduced glucose infusion rate (GIR) and increased
endogenous glucose production (EGP) (Fig. 1e). The phosphor-
ylation levels of Akt in the liver and WAT, but not in the skeletal
muscle, were signiﬁcantly decreased in the MIrs2KO mice after
insulin infusion via the vena cava (Fig. 1f). These data suggest
that the lack of Irs2 in the MΦs causes hepatic and WAT insulin
resistance under the HF diet condition. In fact, the blood glucose
levels during the pyruvate tolerance test (PTT) and expression
levels of phosphoenolpyruvate carboxykinase (PEPCK) and glucose
6-phosphatase (G6Pase) in the liver were signiﬁcantly increased in
the HF diet-fed MIrs2KO mice (Supplementary Fig. 3c, d).
Moreover, the hepatic triglyceride (TG) content was signiﬁcantly
increased in the HF diet-fed MIrs2KO mice (Supplementary
Fig. 3e). There were no signiﬁcant differences in the expression
levels of sterol regulatory element binding protein (SREBP1)c,
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Fig. 1 MΦ Irs2 deﬁciency caused inﬂammation and insulin resistance in the liver and WAT under a HF diet. a Phosphorylation and protein levels of STAT6
and Irs2 in peritoneal MΦs from NC and HF diet-fed mice (n= 4). b, c Expression levels of Irs2 mRNA in the siglecF-CD11b+F4/80+cells of the SVF of the
adipose tissue from ob/ob and HF diet-fed mice (n= 4). d Glucose tolerance test in the MIrs2KO mice (n= 7–14). e GIR, EGP and Rd in the MIrs2KO mice
in the hyperinsulinemic-euglycemic clamp study (n= 9–10). f Phosphorylation levels of Akt (ser473) in the liver, WAT and skeletal muscle of the MIrs2KO
mice after insulin infusion (n= 3–4). g Adipocyte cell size in the MIrs2KO mice (n= 6). h F4/80-positive CLS in the WAT of MIrs2KO mice (scale bar,
200 μm) (n= 6). i Quantitative RT-PCR analysis of the genes encoding inﬂammatory cytokines in the WAT of the MIrs2KO mice (n= 6). The data are
mean ± SEM. followed by one-way ANOVA with a post hoc test or Student’s t test. *P < 0.05; **P < 0.01; ***P < 0.001
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acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS) or
stearoyl-CoA desaturase (SCD)1 between the control and
MIrs2KO mice, whereas the expression levels of PPARγ, fat-
speciﬁc protein (FSP)27 and CD36 were signiﬁcantly increased in
the livers of the HF diet-fed MIrs2KO mice (Supplementary
Fig. 3f). The expression levels of the inﬂammatory cytokines in
the liver were also signiﬁcantly elevated in the HF diet-fed
MIrs2KO mice (Supplementary Fig. 3g). In the WAT, while the
adipocyte cell size was similar between the control and MIrs2KO
mice, F4/80-positive crown-like structures (CLS) were signiﬁ-
cantly increased in the HF diet-fed MIrs2KO mice (Fig. 1g, h).
Moreover, the expression levels of the inﬂammatory cytokines
were also signiﬁcantly increased in the WAT obtained from these
mice (Fig. 1i). These data suggest that a lack of Irs2 in the MΦs
causes insulin resistance and inﬂammation in both the liver and
the WAT under the HF diet condition.
Irs2 deﬁciency impaired M2aΦ activation in obesity. To
investigate whether the polarization of MΦs is altered in the HF
diet-fed MIrs2KO mice, the M1- and M2-type MΦs were ana-
lyzed by ﬂow cytometry. Consistent with the results of the his-
tological analyses (Fig. 1h), the percentage of siglecF-CD11b+F4/
80+ cells was signiﬁcantly increased in the WAT of the HF diet-
fed MIrs2KO mice (Fig. 2a). Although the Irs2 expression levels
in the siglecF-CD11b+F4/80+ cells of the MIrs2KO mice were
markedly reduced, the expression levels of IR, IL-4R and STAT6
did not differ between the control and MIrs2KO mice under the
HF diet condition (Supplementary Fig. 4a). The HF diet-fed
MIrs2KO mice showed an increase in the number of CD11c-
positive cells and decrease in the number of CD206-positive cells
in the ATMs (Fig. 2a). The M1/M2 ratio was signiﬁcantly
increased in the adipose tissue of the HF diet-fed MIrs2KO mice
(Fig. 2a). Consistent with these results, the M2a-subtype MΦ
marker genes were downregulated, whereas some of the M1-type
MΦ marker genes were upregulated in the siglecF-CD11b+F4/80
+ cells of the MIrs2KO mice (Fig. 2b). The expression levels of IL-
10, which is predominantly expressed in M2b-subtype MΦs, were
not signiﬁcantly different between the control and MIrs2KO
mice. The percentage of siglecF+ cells in the SVCs were also not
signiﬁcantly different between the control and MIrs2KO mice
(Supplementary Fig. 4b). These data suggest that the lack of Irs2
in the MΦs led to an increase in the number of M1-type MΦs and
the M1/M2 ratio, and a decrease in the number of M2a-subtype
MΦs in the WAT, resulting in the aggravation of insulin resis-
tance in the MIrs2KO mice under the HF diet condition.
Why did the M1/M2 ratio increase in the WAT of the HF diet-
fed MIrs2KO mice? Since M2a-subtype MΦs are activated by
both IL-4 and IL-1318, we investigated whether it is IL-4 or IL-13
that regulates the M2a-subtype MΦ marker gene expressions
through Irs2. The expression levels of Arg1, FIZZ1, Ym1 and MΦ
galactose N-acetyl-galactosamine-speciﬁc lectin 1 (Mgl1), which
are hallmarks of activated M2a-subtype MΦs, were signiﬁcantly
reduced in the BMDM of the MIrs2KO mice after IL-4
stimulation (Fig. 2c). Consistent with these data, IL-4-induced
arginase activity was also impaired in the BMDM of the MIrs2KO
mice (Fig. 2d). In marked contrast, the expression levels of these
marker genes after IL-13 stimulation were similar between the
control and MIrs2KO mice (Supplementary Fig. 4c). There were
no signiﬁcant differences in the IL-4 and IL-13 levels in the WAT
between the control and MIrs2KO mice under the HF diet
condition (Supplementary Fig. 4d). These data suggest that IL-4-
induced, but not IL-13-induced, M2a-subtype MΦ activation is
impaired in the MIrs2KO mice. There were no signiﬁcant
differences in LPS-induced M1-type activation or MCP-1-
induced BMDM migration between the control and MIrs2KO
mice (Fig. 2e and Supplementary Fig. 4e). Although IL-4 has been
reported to regulate the proliferation of tissue-resident MΦs24,
IL-4-induced BMDM proliferation did not differ between the
control and MIrs2KO mice (Supplementary Fig. 4f). We then
constructed a co-culture system of BMDM derived from
MIrs2KO mice and 3T3-L1 cells. The IL-4 levels were increased
in the conditioned medium of the 3T3-L1 cells, but not BMDM
(Supplementary Fig. 4g), suggesting that IL-4 was secreted from
the 3T3-L1 cells. There was no signiﬁcant difference in the IL-4
level in the conditioned medium between the BMDM of the
control and MIrs2KO mice in co-culture (Supplementary Fig. 4g).
The CCR2 and IL-6 expression levels in the 3T3-L1 cells were
signiﬁcantly higher than those in the BMDM from the MIrs2KO
mice than in the BMDM derived from control mice (Fig. 2f).
These data suggest that impairment of IL-4-induced M2a-subtype
MΦ activation in the BMDM is responsible for the increased M1/
M2 ratio in the HF diet-fed MIrs2KO mice.
We next investigated the molecule mechanisms of IL-4-
induced M2a-subtype MΦ activation via Irs2. Although IL-4-
induced phosphorylation of Irs2 in the BMDM of the control
mice, this phosphorylation was undetectable in the BMDM of the
MIrs2KO mice (Fig. 2g). Moreover, treatment with LY294002, a
PI3 kinase inhibitor, signiﬁcantly inhibited the phosphorylation
of Akt induced by IL-4 in the BMDM (Fig. 2h). IL-4-induced Akt
phosphorylation was signiﬁcantly decreased in the BMDM of the
MIrs2KO mice (Fig. 2i). Consistent with this result, the
expression levels of Arg1, FIZZ1, Ym1 and Mgl1 induced by IL-
4 were signiﬁcantly suppressed by LY294002 treatment (Fig. 2j).
We next examined whether FoxO1 phosphorylation is regulated
by IL-4 in the BMDM. FoxO1 was phosphorylated by IL-4, and
this phosphorylation was inhibited by LY294002 treatment
(Supplementary Fig. 4h). Moreover, immunohistochemical stain-
ing revealed that FoxO1 was translocated from the nucleus to the
cytoplasm after IL-4 stimulation, and that this translocation was
inhibited by LY294002 treatment (Supplementary Fig. 4i).
Consistent with these data, we found that after IL-4 stimulation,
the FoxO1 protein levels were decreased in the nuclear fraction,
whereas they were increased in the cytoplasmic fraction
(Supplementary Fig. 4j). We then investigated whether FoxO1
is involved in M2a-subtype MΦ activation. Transfection of
constitutively active (CA) FoxO1 signiﬁcantly reduced the
expression levels of Arg1, FIZZ1, Ym1 and Mgl1 induced by IL-
4 stimulation (Fig. 2k). IL-4-induced FoxO1 phosphorylation was
signiﬁcantly reduced in the BMDM of the MIrs2KO mice as
compared to the control mice (Fig. 2l), and the decreased
expression levels of the M2a-subtype marker genes in the BMDM
of the MIrs2KO mice were completely restored by siFoxO1
treatment (Fig. 2m). The IL-10 and TNFα expression levels were
signiﬁcantly decreased by IL-4 stimulation and their gene
expression levels did not differ among the three groups. Although
the IL-1β expression levels were also signiﬁcantly decreased by IL-
4 stimulation in all three groups, the transfection of siFoxO1
reduced the expression levels of IL-1β before IL-4 stimulation in
the BMDM of the MIrs2KO mice. No IL-12a or IL-12b expression
was detected in the BMDM (Supplementary Fig. 4k). These data
suggest that IL-4 regulates the PI3 kinase-FoxO1 pathway via
Irs2, which is essential for the activation of M2a-subtype MΦs.
The FoxO1/NCoR1/HDAC3 complex suppressed M2aΦ acti-
vation. To explore the mechanisms underlying FoxO1 mediation
of M2a-subtype MΦ activation induced by IL-4 treatment, we
measured the Arg1 promoter activity with or without CA-FoxO1
treatment using RAW264.7 cells. We ﬁrst conﬁrmed that the Irs2
protein was expressed, and then that IL-4-induced M2a-subtype
MΦ activation and that this activation was inhibited by LY294002
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treatment in the RAW264.7 cells (Supplementary Fig. 5a, b). We
created Arg1 luciferase constructs including enhancer elements
and proximal promoter fragments on the basis of a previous
report25. The enhancer elements contained the STAT6 response
element, which is considered as a STAT6-binding site. Although
the Arg1 promoter activity was signiﬁcantly increased after IL-4
stimulation, this increase was suppressed by CA-FoxO1 treatment
(Fig. 3a). These data suggest that FoxO1 directly regulates IL-4-
induced Arg1 transcript activation. Since we found two FoxO1
consensus sequences in the promoter area of the Arg1 constructs,
we created an Arg1 construct with either A (GTAAATAA →
GTCGATAA) or B (AAAACAA → TCTAGACA) area mutation.
Mutant A promoter activity was signiﬁcantly increased after IL-4
stimulation, and this increase was suppressed by CA-FoxO1
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treatment (Fig. 3a, b; left panel); on the other hand, mutant B and
mutant A plus B promoter activities were not inhibited by CA-
FoxO1 treatment (Fig. 3a, b; middle and right panel). These data
suggest that FoxO1 directly binds to consensus sites including the
B area, and suppresses Arg1 transcript activation induced by IL-4.
Since FoxO1 is known to form a corepressor complex with
HDAC and NCoR1 in the central nervous system26, we investi-
gated whether FoxO1 forms a corepressor complex with HDAC3
and NCoR1 in the RAW264.7 cells by using the electrophoretic
mobility shift assay (EMSA). The EMSA revealed that DNA
nucleotides of the B area in the Arg1 promoter bind to proteins,
and that the DNA-protein complexes were blocked or gel-shifted
in a dose-dependent manner by FoxO1, HDAC3 or NCoR1
antibody (Fig. 3c). Moreover, we performed Chip-qPCR using
FoxO1, HDAC3 or NCoR1 antibody in the Raw 264.7 cells and
BMDM. Although the Arg1 expression levels were signiﬁcantly
increased before IL-4 stimulation, these increases were inhibited
after IL-4 stimulation in both the Raw 264.7 cells and BMDM
(Fig. 3d and Supplementary Fig. 5c). These data suggest that
FoxO1 forms a corepressor complex with HDAC3 and NCoR1,
and that this corepressor complex suppresses Arg1 transcript
activation. Moreover, we performed the Chip-qPCR assay in the
BMDM of the MIrs2KO mice. Although the Arg1 expression
levels were signiﬁcantly increased before IL-4 stimulation, these
increases were not inhibited after IL-4 stimulation in the BMDM
of the MIrs2KO mice (Fig. 3e). There were no signiﬁcant differ-
ences in the FoxO1, HDAC3 or NCoR1 expression levels in the
ATMs between the control and MIrs2KO mice (Supplementary
Fig. 5d). These data suggest that Irs2 is essential for IL-4-induced
dissociation of the FoxO1/HDAC3/NCoR1 corepressor complex
in vivo. To investigate whether FoxO1 directly binds to HDAC3
and NCoR1, we conducted co-immunoprecipitation (Co-IP) with
FoxO1, HDAC3, or NCoR1 antibody without IL-4 stimulation in
the Raw 264.7 cells and BMDM. Co-IP with FoxO1 detected
HDAC3 and NCoR1, Co-IP with HDAC3 detected FoxO1 and
NCoR1, and Co-IP with NCoR1 detected FoxO1 and HDAC3 in
both the Raw 264.7 cells and BMDM (Fig. 3f). These data suggest
that FoxO1 directly binds to HDAC3 and NCoR1. Moreover, IL-
4-induced Arg1 expression was signiﬁcantly increased in the
BMDM transfected with siHDAC3 or siNCoR1 (Fig. 3g). In
addition to Arg1, the FIZZ1 and Ym1 promoter activities were
also signiﬁcantly increased after IL-4 stimulation, although these
increases were suppressed by CA-FoxO1 (Supplementary Fig. 5e).
IL-4-induced FIZZ1 and Ym1 expressions were signiﬁcantly
increased in the BMDM transfected with siHDAC3 or siNCoR1
(Supplementary Fig. 5f). The TNFα and IL-1β expression levels
were signiﬁcantly decreased by IL-4 stimulation, while their gene
expression levels did not differ between the BMDM transfected
and not transfected with siHDAC3 or siNCoR1. No IL-12a or IL-
12b expression was detected in the BMDM (Supplementary
Fig. 5g). These data suggest that FoxO1 directly binds to HDAC3
and NCoR1 and forms a corepressor complex, leading to sup-
pression of M2a-subtype MΦ activation.
MIRKO mice exhibit improved insulin sensitivity. Irs2 is known
as a substrate for not only IL-4R, but also IR. Myeloid cell-speciﬁc
IL-4Rα-deﬁcient (MIL-4RKO) mice showed decreased M2a-subtype
MΦ activation and insulin sensitivity, just like the MIrs2KO mice16.
Thus, we next generated and investigated the phenotypes of
MIRKO mice. As compared to the MIrs2KO mice, the glucose
tolerance was signiﬁcantly better and the plasma insulin levels
signiﬁcantly lower in the MIRKO mice, although there was no
signiﬁcant difference in the BW gain between the two models of
mice (Fig. 4a and Supplementary Fig. 6a). The MIRKO mice
showed increased GIR and reduced EGP in the hyperinsulinemic-
euglycemic clamp study (Fig. 4b). The phosphorylation levels of Akt
in the liver and WAT, but not in the skeletal muscle, were sig-
niﬁcantly increased in the MIRKO mice after insulin infusion via
the vena cava (Fig. 4c). These data suggest that the MIRKO mice
show an improvement of the hepatic and WAT insulin resistance
under the HF diet condition. Consistent with these data, PTT
revealed that the blood glucose levels were lower in the MIRKO
mice than in the control mice, and that PEPCK and G6Pase
expression levels were signiﬁcantly reduced in the livers of the
MIRKO mice (Supplementary Fig. 6b, c). The TG content and gene
expression levels associated with lipogenesis were signiﬁcantly
decreased in the livers of the MIRKO mice (Supplementary Fig. 6d,
e). Moreover, the MIRKO mice also showed a reduction in the
expression levels of the inﬂammatory cytokines in the liver (Sup-
plementary Fig. 6f). In the WAT of the HF diet-fed MIRKO mice,
the number of F4/80-positive CLS was signiﬁcantly decreased,
although there was no signiﬁcant change of the adipocyte cell size
(Fig. 4d, e). The HF diet-fed MIRKO mice showed decreased
inﬂammatory cytokine expression levels in the WAT (Fig. 4f).
Moreover, the number of CD206-positive cells was increased, while
the proportions of siglecF-CD11b+F4/80+ cells, CD11c-positive
cells and the M1/M2 ratio were decreased in the WAT of the HF
diet-fed MIRKO mice (Fig. 4g). Consistent with these results, the
M2a-subtype MΦ maker genes were upregulated, whereas some of
M1-type MΦ marker genes were downregulated in the siglecF-
CD11b+F4/80+ cells of the HF diet-fed MIRKO mice (Fig. 4h). The
expression levels of IL-10 were not signiﬁcantly different between
the control and MIRKO mice. The percentage of siglecF+ cells in
the SVCs, and the IL-4 and IL-13 levels in the WAT did not differ
between the control and MIRKO mice under the HF diet condition
(Supplementary Fig. 6g, h). Although the IL-4R and Irs2 mRNA
expression levels in the BMDM did not differ between the control
Fig. 2 IL-4-induced M2a-subtype MΦ activation was impaired in WAT of the HF diet-fed MIrs2KO mice. a The percentages of siglecF-CD11b+F4/80+,
siglecF-CD11b+F4/80+CD11c+CD206- (M1-type MΦs) and siglecF-CD11b+F4/80+CD11c-CD206+ (M2-type MΦs) cells in the SVF of the adipose tissue
(n= 10–14). b Expression levels of M2-type and M1-type MΦ marker genes in the siglecF-CD11b+F4/80+ cells in the SVF of the adipose tissue from the
control and MIrs2KO mice (n= 10–14). c Expression levels of M2a-subtype MΦ marker genes in the BMDM of the control and MIrs2KO mice after IL-4
stimulation for 48 h (n= 6–8). d Arginase activity in the BMDM of the control and MIrs2KO mice after IL-4 stimulation for 24 h (n= 7–10). e Expression
levels of the M1-type MΦ marker genes in the BMDM of the control and MIrs2KO mice after LPS stimulation for 48 h (n= 3). fMCP-1, CCR2, IL-18 and IL-6
expression levels in 3T3-L1 cells in co-culture with the BMDM of MIrs2KO mice (n= 12). g Irs2 phosphorylation and protein levels in the BMDM of the
control and MIrs2KO mice after IL-4 stimulation (n= 3–4). h Akt phosphorylation and protein levels in the BMDM of the C57BL/6 mice after IL-4
stimulation with or without LY294002 treatment (n= 3). i IL-4-induced Akt phosphorylation in the BMDM of the MIrs2KO mice (n= 4). j Expression
levels of the M2a-subtype MΦ marker genes in the BMDM of the C57BL/6 mice after IL-4 stimulation with or without LY294002 treatment (n= 4–6).
k Expression levels of the M2a-subtype MΦ marker genes in the BMDM of the C57BL/6 mice after IL-4 stimulation with or without CA-FoxO1 treatment
(n= 4–6). l FoxO1 phosphorylation and protein levels in the BMDM of the control and MIrs2KO mice after IL-4 stimulation (n= 3–4). m Expression levels
of the M2a-subtype MΦ marker genes in the BMDM of the MIrs2KO mice after IL-4 stimulation with siFoxO1 transfection (n= 5–6). The data are mean ±
SEM. followed by one-way ANOVA with a post hoc test or Student’s t test. *P < 0.05; **P < 0.01; ***P < 0.001
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Fig. 3 FoxO1 bound to HDAC3 and NCoR1 to form a corepressor complex. a Arg1 promoter activity after IL-4 stimulation with or without CA-FoxO1
transfection (n= 4–5). b Mutant A, B, and A plus B Arg1 promoter activities after IL-4 stimulation with or without CA-FoxO1 transfection (n= 5–6). c The
binding of DNA nucleotides of the B area of the Arg1 promoter and proteins, and the blocking of the DNA-protein complex formation in a dose-dependent
manner by FoxO1, HDAC3 and NCoR1 antibody were determined by EMSA in RAW264.7 cells. d Chip-qPCR using FoxO1, HDAC3 and NCoR1 antibody in
the BMDM of the C57BL/6 mice before and after IL-4 stimulation (n= 5–10). e Chip-qPCR using FoxO1, HDAC3 and NCoR1 antibody in the BMDM of the
MIrs2KO mice before and after IL-4 stimulation (n= 3–16). f Co-immunoprecipitation (Co-IP) with FoxO1, HDAC3 and NCoR1 antibody without IL-4
stimulation in the Raw 264.7 cells and BMDM. g Expression levels of Arg1 in the BMDM of the C57BL/6 mice after IL-4 stimulation with siHDAC3 or
siNCoR1 transfection (n= 3–8). The data are mean ± SEM. followed by one-way ANOVA with a post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001
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Fig. 4MIRKO mice exhibited improved insulin sensitivity and glucose tolerance. a Glucose tolerance test in the MIRKO mice (n= 7–13). b GIR, EGP and Rd
in the MIRKO mice in the hyperinsulinemic-euglycemic clamp study (n= 8–9). c Phosphorylation levels of Akt (ser473) in the liver, WAT and skeletal
muscle of the MIRKO mice after insulin infusion (n= 3–4). d Adipocyte cell size in the MIRKO mice (n= 4–6). e F4/80-positive CLS in the WAT of the
MIRKO mice (scale bar, 200 μm) (n= 4–6). f Quantitative RT-PCR analysis of the genes encoding inﬂammatory cytokines in the WAT of the MIRKO mice
(n= 4–6). g The percentages of siglecF-CD11b+F4/80+, siglecF-CD11b+F4/80+CD11c+CD206- (M1-type MΦs) and siglecF-CD11b+F4/80+CD11c-CD206
+ (M2-type MΦs) cells in the SVF of the adipose tissue from the MIRKO mice (n= 4–6). h Expression levels of M2-type and M1-type MΦmarker genes in
the siglecF-CD11b+F4/80+ cells in the SVF of the adipose tissue from the control and MIRKO mice (n= 4–5). Data are mean ± SEM. followed by one-way
ANOVA with a post hoc test or Student’s t test. *P < 0.05; ***P < 0.001
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and MIRKO mice under the NC diet condition, the IR mRNA and
protein expressions were almost completely abrogated in the
BMDM of the MIRKO mice (Supplementary Fig. 6i, j). There were
no signiﬁcant differences in the BW, ITT, GTT or lipid proﬁles
between the control and MIRKO mice under the NC diet condition
(Supplementary Fig. 6k-n). These data suggest that the lack of IR in
the MΦs led to a decrease in the number of M1-type MΦs and the
M1/M2 ratio, and an increase in the number of M2a-subtype MΦs
in the WAT, resulting in the protection of insulin resistance in the
MIRKO mice under the HF diet condition.
Irs2 expressions and M2aΦ activation increased in MIRKO
mice. Unlike the MIrs2KO mice, why did the M1/M2 ratio
decrease in the WAT of the HF diet-fed MIRKO mice? We
analyzed the expression levels of IR, Irs2, IL-4R, STAT6 in the
ATMs of the MIRKO mice. Although the IL-4R and STAT6
expression levels were not signiﬁcantly different, the expression
levels of Irs2 were signiﬁcantly higher in the siglecF-CD11b+F4/
80+ cells isolated from the WAT of the MIRKO mice (Fig. 5a).
Moreover, the IL-4-induced Irs2 and Akt phosphorylation were
signiﬁcantly enhanced in the peritoneal MΦs of HF diet-fed
MIRKO mice, along with increased MΦ Irs2 expression, although
IL-4-induced STAT6 phosphorylation did not differ between
control and MIRKO mice (Fig. 5b and Supplementary Fig. 7a).
These data suggest that M2a-subtype MΦ activation was caused
by enhanced IL-4-induced Irs2/Akt pathway along with increased
Irs2 expression levels in the MIRKO mice reared on a HF diet. IR
signaling has been shown to suppress the expression of Irs2, both
in vitro and in vivo, by inhibiting the synthesis of Irs2 mRNA at
the transcriptional level in organs such as the liver and endo-
thelial cells27–30. Thus, we investigated the contribution of IR
signaling to the expression levels of Irs2 in the MΦs. Transfection
of siFoxO1 reduced the Irs2 expression in BMDM (Supplemen-
tary Fig. 7b). Although insulin stimulation markedly suppressed
the expression of Irs2 along with translocation of FoxO1 from the
nucleus to the cytosol in the BMDM of the control mice (Sup-
plementary Fig. 7c), this downregulation was not observed in the
BMDM from the MIRKO mice (Fig. 5c). These data suggest that
M2a-subtype MΦ activation via the IL-4/Irs2 pathway is main-
tained in MIRKO mice, resulting in reduced inﬂammation and
insulin resistance, as Irs2 expression in the MΦs of the MIRKO
mice is not downregulated by insulin. We next investigated the
expression levels of Irs2 in the peritoneal MΦs of the mice after
streptozotocin (STZ) plus phlorizin treatment. While the plasma
insulin levels were signiﬁcantly reduced, the peritoneal MΦ Irs2
expression levels were signiﬁcantly increased in the STZ plus
phlorizin-treated mice (Supplementary Fig. 7d), suggesting that
hyperinsulinemia downregulates MΦ Irs2 expression in vivo.
Downregulation of Irs2 expression levels by pretreatment with
insulin was associated with signiﬁcantly reduced expressions of
IL-4-induced M2a-subtype marker genes in the BMDM, while
having no effect on the expression levels of IR and IL-4R (Fig. 5d
and Supplementary Fig. 7e). The decreased IL-4-induced Arg1
expression in the BMDM after insulin pretreatment was com-
pletely restored by siFoxO1, siNCoR1, or siHDAC3 treatment
(Fig. 5e). Moreover, when the BMDM were co-cultured with 3T3-
L1 cells in the presence of insulin, signiﬁcant downregulation of
the Irs2 expression in the BMDM and signiﬁcant upregulation of
MCP-1, CCR2, IL-18 and IL-6 expressions in the 3T3-L1 cells
were observed (Fig. 5f and Supplementary Fig. 7f, g).
M2aΦ activation is regulated by both Irs2 and STAT6 path-
ways. Why did insulin fail to induce M2a-subtype MΦ activation,
although it could activate Irs2 as well as IL-4? Although insulin
induced phosphorylation of Akt to the same level as that induced
by IL-4, it failed to induce M2a-subtype MΦ activation (Fig. 6a,
b). These data suggest that IL-4-induced M2a-subtype MΦ acti-
vation is not mediated by the Irs2/Akt/FoxO1 pathway alone.
Since IL-4 is well known to regulate M2a-subtype MΦ activation
via the STAT6 pathway18, we investigated STAT6 phosphoryla-
tion induced by IL-4 or insulin stimulation. While IL-4-induced
phosphorylation of STAT6, insulin failed to do so (Fig. 6c). As in
the case of the BMDM lacking Irs2, IL-4-induced M2a-subtype
activation was reduced in the BMDM transfected with siSTAT6
(Fig. 6d). IL-4-induced STAT6 phosphorylation in the BMDM
did not differ between the control and MIrs2KO mice, but this
phosphorylation was not induced by insulin in the
BMDM (Fig. 6e). Moreover, LY294002 treatment inhibited IL-4-
induced Akt phosphorylation, but had no effect on IL-4-induced
STAT6 phosphorylation (Figs. 2h, 6f). Consistent with these -
data, no differences were found in the expression levels of PGC1β
or PPARγ, which are STAT6-associated genes, between
the control and MIrs2KO mice after IL-4 treatment (Supple-
mentary Fig. 8). These data suggest that IL-4 regulates M2a-
subtype MΦ activation through both the STAT6 signaling and
Irs2/Akt signaling pathways. In contrast, insulin rather sup-
pressed IL-4-induced M2a-subtype MΦ activation via down-
regulation of Irs2.
Discussion
In this study, we demonstrated that IL-4/Irs2/Akt pathway was
essential for activation of M2a-subtype MΦs, in addition to IL-4/
STAT6 pathway. Activation of both pathways was necessary for
the full activation of M2a-subtype MΦs (Fig. 7, left panel). In
obesity, although IL-4/STAT6 pathway was preserved, IL-4/Irs2/
Akt pathway was selectively impaired due to downregulation of
Irs2 induced by hyperinsulinemia via IR signaling, leading to
impaired signaling in the IL-4/Irs2/Akt pathway and M2a-
subtype MΦ activation by stabilization of the FoxO1/HDAC3/
NCoR1 corepressor complex (Fig. 7, right panel). These data
suggest that in obesity, hyperinsulinemia plays crucial roles in the
dysregulation of M2a-subtype MΦ activation due to down-
regulation of Irs2 expression.
The chronic hyperinsulinemia induced by sustained over-
nutrition, such as in animals reared on a HF diet, promotes
adipocyte hypertrophy and obesity. In fact, adipose tissue-speciﬁc
IRKO mice with gold thioglucose (GTG)-induced obesity exhib-
ited a smaller adipocyte size in spite of hyperinsulinemia31.
Enlarged adipocytes in response to hyperinsulinemia release
inﬂammatory cytokines such as MCP-1 and TNFα, leading to
inﬂammatory monocytic inﬁltration of the WAT32. The inﬁl-
trating monocytes differentiate into M1-type MΦs and form CLS
around dead adipocytes. The M1-type MΦs in the CLS also
express inﬂammatory cytokines, thereby driving the development
of insulin resistance. In fact, M1-type MΦs were recruited in mice
showing overexpression of MCP-1 in the adipose tissue, resulting
in the development of insulin resistance33. On the other hand, in
this study, we found that hyperinsulinemia downregulated Irs2
expression, which led to impaired M2a-subtype MΦ activation.
These data suggest that chronic hyperinsulinemia causes both
increased M1-type MΦ activation via inducing adipocyte hyper-
trophy and decreased M2a-subtype MΦ activation via Irs2
downregulation, thereby leading to the development of inﬂam-
mation and insulin resistance.
Previous studies have demonstrated that MIRKO mice are
protected from obesity-induced inﬂammation and insulin resis-
tance under the HF diet condition. The obesity-associated MΦ
inﬁltration of the adipose tissue was signiﬁcantly reduced in these
mice34. On the other hand, mice lacking 3-phosphoinositide-
dependent protein kinase 1 (PDK1) in the myeloid cells, which are
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Fig. 5 The Irs2 mRNA levels and number of M2a-subtype MΦs were elevated in HF diet-fed MIRKO mice. a Expression levels of IR, IL-4R, Irs2 and STAT6 in
the siglecF-CD11b+F4/80+ cells of the SVF of the adipose tissue from the control and MIRKO mice (n= 4–6). b IL-4-induced STAT6, Irs2 and Akt
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4-induced Arg1 expression levels in the BMDM pretreated with 100 nM insulin for 8 h after siFoxO1, siNCoR1, or siHDAC3 treatment (n= 4–16). f MCP-1,
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downstream signaling molecules in the IR/Irs2 pathway, showed
adipose tissue inﬂammation and insulin resistance under the HF
diet condition35. The results from the MIRKO mice suggest that
impaired insulin signaling in MΦs improved obesity-induced
inﬂammation and insulin resistance. On the other hand, impaired
insulin signaling in the MΦs of PDK1KO mice aggravated
inﬂammation and insulin resistance. Thus, in terms of the effects
of insulin signaling, there seem to be discrepancies in the
phenotypes between the MIRKO and PDK1KO mice. However,
this could be interpreted by analyzing the effects of IL-4 signaling
in an integrated fashion. As seen in this study (Fig. 7), in the
MIRKO mice, MΦ Irs2 downregulation by insulin is suppressed
and M2a-subtype MΦ activation via the IL-4 signaling pathway is
preserved. Although MΦ Irs2 downregulation by insulin may also
be suppressed in the PDK1KO mice, as in the MIRKO mice, the
IL-4 signaling pathway in the MΦs is impaired downstream of Irs2
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in these mice, because PDK1 is a downstream molecule not only
in the insulin signaling pathway, but also in the IL-4 signaling
pathway. In fact, mice overexpressing CA-FoxO1 in the myeloid
cells, which is thought to be associated with maintained Irs2
expression and decreased IL-4 signaling due to stabilization of
FoxO1/HDAC3/NCoR1 corepressor complex in the MΦs, showed
reduced M2a-subtype MΦ activation and increased inﬂammation
and insulin resistance under the HF diet condition35. These data
suggest that IR signaling contributes to IL-4 signaling via reg-
ulating Irs2 expression, mediating obesity-induced inﬂammation
and insulin resistance under the HF diet condition.
Similar to the ﬁnding in the WAT, inﬂammation and insulin
resistance were also noted in the livers of the MIrs2KO mice.
Increased inﬂammatory cytokine release from the adipose tissue
may cause hepatic insulin resistance. In fact, hepatic insulin
resistance was observed in mice showing overexpression of MCP-
1 in the adipose tissue, along with increased release of inﬂam-
matory cytokines such as TNFα and IL-633. +Kupffer cells,
which are the resident MΦs in the liver, have been reported to
contribute to hepatic inﬂammation and insulin resistance5,32.
PPAR-δ deﬁciency has been shown to impair M2a-subtype MΦ
activation in Kupffer cells, thereby aggravating hepatic inﬂam-
mation and insulin resistance in obesity11,12. In addition to
Kupffer cells, M1-type MΦs are recruited to the liver from the
BM in obesity. The recruited hepatic MΦs are similar to the M1-
type MΦs in the adipose tissue36, and induce activation of
proinﬂammatory pathways in the hepatocytes, thereby causing
hepatic insulin resistance. Depletion of Kupffer cells and of the
recruited hepatic MΦs using gadolinium or clodronate protected
the mice from obesity-induced hepatic insulin resistance37,38.
These data suggest three possibilities in respect of the mechanism
underlying the hepatic inﬂammation and insulin resistance
observed in MIrs2KO mice: increased inﬂammatory cytokine
release from the adipose tissue, decreased M2a-subtype MΦ
activation caused by Irs2 deﬁciency in the Kupffer cells, and/or
newly recruited M1-type MΦs in the liver.
Why was M2a-subtype MΦ activation maintained under the
NC diet condition in spite of the fact this activation decreased
under the HF diet condition in the MIrs2KO mice (Fig. 2a and
Supplementary Fig. 2g)? There are two possibilities: induction of
compensatory pathways in an IL-13-dependent or IL-13-
independent manner. In type I receptor deﬁciency, M2a-
subtype MΦ activation was indeed shown to be induced by IL-
1339. In type II receptor deﬁciency, on the other hand, IL-4
induced M2a-subtype MΦ activation21, suggesting that both IL-4
and IL-13 activates M2a-subtype MΦs vice versa. Mice with
systemic STAT6 KO and myeloid-speciﬁc IL-4Rα KO, which
show defect in both IL-4 and IL-13 signaling, exhibited a sig-
niﬁcant reduction of M2a-subtype MΦ activation in the ATMs
under the NC diet condition16. In this study, although IL-4-
induced M2a-subtype activation was impaired in the BMDMs of
the MIrs2KO mice, IL-13-induced M2a-subtype activation was
maintained in these cells. Jmjd3-IRF4 pathways have also been
reported to induce M2a-subtype MΦ activation independently of
the IL-13 signaling pathways40. These data suggest that the M2a-
subtype MΦ activation observed in NC-fed MIrs2KO mice may
be compensated for in both an IL-13-dependent and IL-13-
independent manner.
In this study, we found that in obesity, the hyperinsulinemia
presumably downregulates MΦ Irs2 expression, resulting in
impaired IL-4-induced M2a-subtype MΦ activation, and conse-
quently, development of inﬂammation and insulin resistance in
the liver and WAT.
Methods
Animals. To generate mice with targeted deletion of Irs2 in the myeloid lineage
cells, mice with ﬂanking loxP Irs2 alleles (Irs2lox/lox) were crossed with
LysozymeM-Cre transgenic mice41,42. Genotyping was performed by PCR ampli-
ﬁcation of the tail DNA from each mouse at 4 weeks of age, as previously repor-
ted30. To generate mice with targeted deletion of the IR in the myeloid lineage cells,
we created IRlox/lox mice, carrying the IR allele with loxP sites ﬂanking exon 4
(Supplementary Fig. 9a). The targeting construct to introduce loxP sites into the IR
gene was created from a 13-kb clone of the IR gene containing exon 4, as described
previously, but with slight modiﬁcation34. A targeting vector with the ﬂoxed
neomycin-resistance gene was introduced into the 5′ side of the IR gene, and the
loxP gene was introduced into the 3′ side (Supplementary Fig. 9a). The construct
was transfected into J1 embryonic stem cells (129/Sv) by electroporation and
screened for homologous recombinant clones by Southern blot analysis. The cells
were injected into blastocysts from C57BL/6 mice and transferred into pseudo-
pregnant ICR female mice to generate heterozygous mice, as previously reported41.
To generate MIRKO mice, IRlox/lox mice were crossed with LysozymeM-Cre
transgenic mice. The PCR primers used for the Cre recombinase were 5′-
ACATGTTCAGGGATCGCCAGG-3′ and 5′-TAACCAGTGAAACAGCATTGC-
3′. To detect Cre-mediated recombination at the genomic DNA level in the BMDM
by PCR, we designed primers for the upstream portion of the IR genomic DNA
(primer a), Neo DNA (primer b), and the downstream portion of the IR genomic
DNA (primer c). Primer a was 5′-TGCCTAGAGACTCCAAGACAAA-3′, primer
b was 5′-CAGCGCATCGCCTTCTATCGCCTTC-3′ and primer c was 5′-
CTGCAAAAAGGAGGAAATGC-3′, Primer pairs ‘a’ and ‘b’ or ‘a’ and ‘c’ yielded
PCR products about 250 bp and 627 bp in length before and after Cre-mediated IR
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Fig. 7 Scheme illustrating the mechanism of impaired IL-4-induced M2a-subtype MΦ activation in obesity. IL-4/Irs2/Akt pathway was essential for
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deletion, respectively (Supplementary Fig. 9b). Although the original MIrs2KO and
MIRKO mice were derived from a C57BL/6 and 129/Sv mixed background, these
mice were backcrossed more than eight times with C57BL/6 mice. All experiments
in this study were performed using male littermates, and Irs2lox/lox and IRlox/lox
mice were used as the controls. The mice were housed under a 12-h light/dark cycle
at 22.5–23.5 °C and given access to food ad libitum. Standard (CE-2) and HF (HF-
32) diets were also purchased from Japan CLEA. The composition of the HF diet
was: 20% safﬂower oil, 15.8% beef tallow, 24.5% casein, 6.75% sucrose, 5.5% cel-
lulose, 5.0% mineral mixture, and 1.4% vitamin mixture. The HF diet was admi-
nistered to the mice for 17–20 weeks starting at 8 weeks of age. The animal care
and experimental procedures used in this study were approved by the Animal Care
Committee of the University of Tokyo.
Isolation of the peritoneal MΦs and ﬂow cytometry. Mice were injected
intraperitoneally with 3% sodium thioglycollate (Wako). After four days, peritoneal
MΦs were collected and stimulated with IL-4. Epididymal adipose tissue specimens
isolated from mice were rinsed in PBS, minced into ﬁne pieces, and digested with
Tyrode buffer (130 mM NaCl, 5.4 mM KCl, 0.5 mM MgCl2, 0.33 mM NaH2PO4,
22 mM glucose, 5 mM L-glutamine, and 25 mM HEPES) containing collagenase
(Worthington) at 37 °C using a water bath for 15 min. Then, the samples were
passed through a mesh and centrifuged in a swing rotor at 362 × g. The pellets were
collected as the stromal-vascular fraction (SVF), and the SVF cells were incubated
in 1× Pharm Lyse (BD Biosciences) for 8 min at room temperature. The cells were
suspended in PBS containing 2% BSA, and incubated with anti-CD16/32 (553142,
BD pharmingen) for 5 min on ice. Then, the cells were incubated with the primary
antibodies or the matching control isotypes for 1 h on ice, and analyzed using a
FACS Aria II cell sorter (BD Biosciences) and FlowJo (Tree Star, Ashland, OR).
SiglecF-negative/F4/80-positive/CD11b-positive cells were sorted and used for the
RNA extraction. Furthermore, the cells were also divided CD11c-positive/CD206-
negative and CD11c-negative/CD206-positive cells, as M1-type and M2-type MΦs,
respectively.
Glucose and pyruvate tolerance test. Mice were loaded with oral glucose at 1.5
mg/g body weight after being denied access to food for 24 h. Blood samples were
taken at different time-points and the blood concentrations of glucose were
measured with an automatic glucometer (Glutest Ace, Sanwa Chemical Co.,
Nagoya, Japan). Blood samples were collected and centrifuged in heparinized tubes,
and the separated plasma samples were stored at −20 °C. Insulin levels were
determined using a mouse insulin ELISA kit (Morinaga). Pyruvate tolerance test
were performed after the animals were denied access to food for 16 h. The mice
were injected intraperitoneally with pyruvate dissolved in saline (1.5 g/kg), and
blood samples were obtained from the tail vein at different time-points.
Hyperinsulinemic-euglycemic clamp. An infusion catheter was inserted into the
right jugular vein of the mice, as described previously30. To measure the GIR, a
primed-continuous infusion of insulin (Humulin R; Lilly) was administered at the
dose of 7.5 milliunits/kg/min to the HF-diet-fed mice, and the blood glucose
concentration, monitored every 5 min, was maintained at approximately 120 mg/dl
by the administration of glucose (5 g of glucose/10 ml enriched to about 20% with
[6,6–2H2]glucose (Sigma)) for 120 min. Blood samples (20 μl) were obtained for 15
or 30 min before the end of the hyperinsulinemic-euglycemic clamp. Thereafter,
the Rd was calculated according to nonsteady-state equations, and the EGP was
calculated as the difference between the Rd value and the exogenous GIR.
Insulin signaling in the liver, eWAT and skeletal muscle. To investigate the
insulin signaling in the liver, eWAT and skeletal muscle, insulin (6 ng/ml)
(Humulin R; Lilly) was injected via the inferior vena cava. The liver, eWAT and
skeletal muscle were dissected 10 min after the insulin infusion and immediately
frozen in liquid nitrogen. The samples were then analyzed by western blot analysis.
Hepatic TG content. For determining the hepatic TG content, each liver sample
was homogenized in buffer A (25 mM Tris-HCl, pH 7.4, 10 mM sodium ortho-
vanadate, 10 mM sodium pyrophosphate, 100 mM sodium ﬂuoride, 10 mM EDTA,
10 mM EGTA and 1 mM phenylmethylsulfonyl ﬂuoride), as previously reported31.
2:1 (vol/vol) chloroform/methanol was added to the homogenate and the mixture
was shaken for 15 min. After centrifugation at 17,753 × g for 10 min, the organic
layer was collected. This extraction was repeated three times, and the collected
samples were dried and resuspended in 1% Triton X-100/ethanol. The TG content
in the extracted sample was measured using Triglyceride E-test Wako (Wako Pure
Chemical Industries Ltd., Osaka, Japan).
Immunohistochemistry. eWAT specimens were ﬁxed with 10% formalin and
embedded in parafﬁn. Quantiﬁcation of the adipocyte size and F4/80-positive area
were carried out using the image analyzer software, Win ROOF (Mitani Corp), as
previously reported41. The BMDM were also ﬁxed in 4% paraformaldehyde in PBS
for 30 min on ice and blocked using 3% bovine serum albumin (BSA)/PBS for at
least 1 h at room temperature. FoxO1 (2880, Cell signaling, 1:100) antibody was
added, followed by incubation in blocking buffer (3% BSA/PBS) overnight at 4 °C.
The antibody reactivity was detected using Alexa Fluor 488-conjugated anti-rabbit
IgG, a diaminobenzidine (DAB) substrate (Pierce). Fluorescence images were
acquired using an Olympus IX71 microscope.
Bone marrow-derived MΦs. Bone marrow cells were isolated from the femur,
tibia and humerus bones of the mice, as previously reported30. The cells, suspended
in RPMI-1640 medium (supplemented with 15% FCS, 1% penicillin-streptomycin)
were plated. The ﬂoating cells were collected after incubation for 16 h and plated at
a concentration of 1 × 106 cells/ml in RPMI-1640 medium (supplemented with
15% FCS, 1% penicillin-streptomycin and 50 ng/ml recombinant M-CSF (She-
nandoah biotechnology)) in 10-cm Petri dishes and allowed to differentiate for
8–10 days. For M1-type MΦ activation, the BMDM were treated with 5 ng/ml of
LPS (Sigma), while for M2a-subtype MΦ activation, the cells were treated with 10
ng/ml of IL-4 (Peprotech) or 20 ng/ml of IL-13 (Peprotech). The cells were exposed
to a PI3 kinase inhibitor (10 µM LY294002) 30 min before the addition of IL-4.
Immunoprecipitation and western blot analysis. To prepare the lysates, the cells
and tissues were homogenized in buffer A (25 mM Tris-HCl, pH 7.4, 10 mM
sodium orthovanadate, 10 mM sodium pyrophosphate, 100 mM sodium ﬂuoride,
10 mM EDTA, 10 mM EGTA and 1 mM phenylmethylsulfonyl ﬂuoride). For
immunoprecipitation of Irβ, Irs1 and Irs2, the lysates were incubated with rabbit
polyclonal antibody against Irβ (sc-711, Santa Cruz), Irs1 (06–248, Millipore) or
Irs2 (3089, Cell Signaling) for 1 h at 4 °C. Then, protein G-Sepharose was added,
followed by incubation for a further 1 h at 4 °C. Thereafter, after washing 3 times
with buffer A, the immunocomplexes were resolved on 7% or 10% SDS-PAGE.
Phosphorylated or total protein was analyzed by immunoblotting using speciﬁc
antibodies against Irβ, Irs1, Irs2 and phosphotyrosine. Phosphorylated or total
protein of Akt, FoxO1 and STAT6 was isolated by immunoblotting using speciﬁc
antibodies after the tissue lysates were resolved by SDS-PAGE and transferred to a
Hybond-P PVDF transfer membrane (Amersham Biosciences). Bound antibodies
were detected with HRP-conjugated secondary antibodies using ECL detection
reagents (Amersham Biosciences). Uncropped scans of the blots can be found as a
Supplementary Figure in the Supplementary Information (Supplementary Fig. 10
and Supplementary Fig. 11).
RNA extraction and real-time PCR. RNA was isolated from the cells and tissues
with the Qiagen RNeasy Kit (Qiagen, Germany), in accordance with the manu-
facturer’s instructions. One microgram of RNA was used for generating cDNA
using random hexamers with MultiScribe reverse transcription reagents (ABI).
TaqMan quantitative PCR (cycles of 50 °C for 2 min, 95 °C for 10 min, followed by
40 cycles of 95 °C for 15 s, 60 °C for 1 min) was then performed with ABI Prism
7900 PCR (Applied Biosystems) to amplify IR (Mm 00439693_m1), Irs1
(Mm00439720_s1), Irs2 (Mm03038438_m1), IL-4R (Mm00439634_m1), STAT6
(Mm01160477_m1), Arg1 (Mm00475988_m1), FIZZ1 (Mm00445109_m1), Ym1
(Mm00657889_mH), Mgl1 (Mm0054612_m1), IL-10 (Mm00439614_m1), TNFα
(Mm 00443258_m1), MCP-1(Mm00441242_m1), IL-6 (Mm00446190_m1), CCR2
(Mm99999051_gH), IL-1β (Mm00434228_m1), IL-18 (Mm00434225_m1), PEPCK
(Mm00440636_m1), G6Pase (Mm 00839363_m1), ACC (Mm01304287_m1), FAS
(Mm01253300_g1), SCD1 (Mm00772290_m1), PPARγ (Mm00440945_m1), FSP27
(Mm00617672_m1), CD36 (Mm 00432403_m1), PGC1β (Mm01258518_m1),
PPARδ (Mm01305434_m1), IL-12a (Mm00434169_m1), IL-12b
(Mm01288989_m1), and β-actin (Mm00607939_s1) cDNA from the samples. The
primers for the other reactions were purchased from Applied Biosystems. The
expression level of each of the transcripts was normalized to the constitutive
expression level of β-actin mRNA.
Arginase assays. After the BMDM (5.0 × 106 cells) were stimulated with IL-4 for
48 h, the cells were collected in ice-cold PBS. The cells were then lysed in buffer
containing 0.4% Triton-X-100 and protease inhibitors, and the arginase activity
were measured using the Arginase Assay Kit (Abnova), according to the manu-
facturer’s instructions. The lysed cells were centrifuged at 14,000 × g at 4 °C for 10
min, and the supernatants were plated on to a 96-well microtiter plate. L-arginine
was converted to urea by a buffer containing a substrate and cofactor, and the
absorbance of the samples was measured using a microplate reader at the wave-
length of 430 nm.
siRNA transfections and adenovirus-mediated gene transfer. The BMDM were
transfected with adenovirus containing murine cDNA encoding FoxO1-T24A/
S253D/S316A43. Five days later, the cells were treated with IL-4 and the harvested
samples were then used for the gene expression analyses. The Neon® Transfection
System (Invitrogen) was used for the siRNA transfection. The BMDM were sus-
pended at the density of 1.2 × 107 cells/ml in resuspension buffer T (Invitrogen),
and incubated with 200 mM of siRNA (siFoxO1, 7892394, Invitrogen; siHDAC3,
s67421, Ambion; siNCoR1, s73229, Ambion; siSTAT6, sc-36570, Sant Cruz; siCont,
4390843, Ambion). The pulse conditions were as follows: square wave, 1600 V, 1
pulse, 20 ms pulse length. The RNAi efﬁciency was conﬁrmed by quantitative real-
time PCR and the silenced BMDM were used for the functional assays 72–96 h
after the electroporation. BMDM transfected with siRNA were stimulated with 10
ng/ml IL-4 for 20 h after pretreatment with 100 nM of insulin for 8 h.
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Dual luciferase assays. Several DNA fragments containing the mouse Arg1, FIZZ1
and Ym1 promoters were PCR-ampliﬁed from mouse genomic DNA. The PCR
products were ligated using the pGEM-T Easy vector (Promega) and their nucleotide
sequences were veriﬁed by DNA sequencing. Mutation of the Arg1 promoter was
produced using the PrimerSTAR mutagenesis basal kit (Takara). These promoter
fragments were cloned into the luciferase reporter pGL3-Basic vector (Promega,
Madison, WI). Transfection was carried out at 70–80% conﬂuence of the RAW264.7
cells (Cat. No. EC91062702, DS Pharma Biomedical) using 2.25 μg of the Arg1-,
FIZZ1-, or Ym1-luciferase reporter gene (pGL3); 0.5 μg of the Renilla luciferase
reporter vector (phRL-SV40; Promega) was used as the internal control for deter-
mining the transfection efﬁciency. After the cells were transfected using the Neon
transfection system (Invitrogen), the transfected cells were treated with 10 ng/ml of
IL-4 for 24 h. The luciferase activities were measured using the Dual-Glo Luciferase
Assay System (Promega), according to the manufacturer’s protocol.
EMSA. Nuclear protein extracts were prepared from RAW 267.4 cells before IL-4
treatment. A double-stranded oligonucleotide containing the consensus forkhead
binding region in the Arg1 promoter area was labeled using the Biotin 3′ End DNA
Labeling Kit (PIERCE). This biotin-labeled oligonucleotide probe (20 fmol) was
incubated with the nuclear extracts in the presence of 10 mM Tris-HCl (pH 7.5),
50 mM NaCl, 1 mM MgCl2, 0.5 mM EDTA, 4% glycerol and 0.5 mM DTT for 20
min at room temperature using the LightShift® Chemiluminescent EMSA Kit
(Thermo scientiﬁc). For the competition experiments, the nuclear extracts were
incubated with 0, 1, 2 or 5 μl of anti-FoxO1 (2880, Cell Signaling), anti-HDAC3
((3949, Cell Signaling) or anti-NCoR1 (5948, Cell Signaling)) antibody, or an equal
amount of normal rabbit or IgG (sc-2027, Santa Cruz) for 60 min at room tem-
perature. The non-denaturing binding reaction mixture was applied for electro-
phoresis on 6% polyacrylamide gels. The nylon membrane transferred from the
gels was crosslinked using a commercial UV-light crosslinking instrument equip-
ped with 254 nm bulbs and visualized by chemiluminescence.
Co-culture system. 3T3-L1 preadipocytes (ECACC 86052701) were purchased
from DS Pharma Biomedical Co., Ltd. Co-culture was performed using the
Transwell system (Merck Millipore) with a 0.4 μm porous membrane to separate
the upper chambers from the lower ones, as previously described, with some
modiﬁcations12. In the lower chambers, 3T3-L1 preadipocytes were seeded into 12-
well plates at 0.8 × 104 cells per well and cultured to conﬂuence in 3T3-L1 pre-
adipocyte medium (DS Pharma Biomedical Co., Ltd). At 2 days post conﬂuence,
the cells were induced to differentiate using the 3T3-L1 differentiation medium (DS
Pharma Biomedical Co., Ltd), and then used after 8 days. The BMDM of the
control, MIrs2KO or C57BL/6 mice were plated at a concentration of 1 × 106 cells/
ml in 10 cm Petri dishes containing RPMI-1640 medium and allowed to differ-
entiate for 8 days. The BMDM (0.8 × 106 cells per well) were plated into the upper
chambers. Twenty-four hours after the plating, FCS and M-CFS-free RPMI 1640
medium plus 100 nM insulin were added to the BMDM and 3T3-L1 adipocyte
cultures. After further incubation for 24 h, the conditioned medium, 3T3-L1 cells
and BMDM were collected and analyzed. The measurements of IL-4 (Abcam) and
IL-13 (Cusabio) were conducted using mouse ELISA kits.
ChIP assay. BMDM (0.8 × 106 cells) were plated in 10-cm dishes and stimulated or
not stimulated with 10 ng/ml of IL-4. The cells were ﬁxed with 37% paraf-
ormaldehyde for 10 min at room temperature, and quenched with glycine for 5 min
at room temperature. The collected cells were lysed using a buffer containing
protease inhibitor from a shearing ChIP kit (Diagenode). The cells were sonicated
for 18 cycles (30 s “ON”, 30 s “OFF”) at 200W on ice using an ultrasonic homo-
genizer (Bioruptor UCW-310, Cosmo Bio Co.) to shear chromatin. Samples were
diluted to 1.8 ml with the ChIP Dilution Buffer (50 mM Tris-HCL pH 8, 167 mM
NaCl, 1.1% Triton X-100, 0.11% sodium deoxycholate, protease inhibitor cocktail)
and precleared for 2 h at 4 °C with 50% protein G sepharose/salmon sperm DNA.
After removal of the sepharose beads by centrifugation, immunoprecipitation was
performed with ChIP-graded anti-FoxO1 (sc-11350, Santa Cruz, 1:50) HDAC3 (sc-
11417, Santa Cruz, 1:50) and NCoR1 (sc-1609, Santa Cruz, 1:50) antibodies or an
equal amount of normal rabbit (sc-2027, Santa Cruz, 1:50) or goat IgG (sc-2028,
Santa Cruz, 1:50), followed by incubation overnight at 4 °C; then, precipitation of
the antibody-protein-DNA complexes with 50% protein G sepharose/salmon
sperm DNA was performed for 2 h at 4 °C. The precipitates were sequentially
washed with buffers containing 0.1% SDS, 1% Triton X-100, 2 mM EDTA, and 20
mM Tris-HCl (pH 8.1) supplemented with either 150 mM (buffer I) or 500 mM
NaCl (buffer II), prior to a ﬁnal wash in 250 mM LiCl, 1% NP-40, 1% deoxycholate,
1 mM EDTA and 10 mM Tris-HCl (pH 8.1). The pellets were washed with Tris-
EDTA buffer and extracted with 1% SDS, 10 mM EDTA and 50mM Tris-HCl (pH
8.0). After heating at 65 °C overnight, the proteins were digested with proteinase K,
and the DNA was puriﬁed. The samples were subjected to PCR using the following
primers: for Arg1: 5′-GAATAGCACTTGGCACACGA-3′ and 5′-ACACTGTC-
TAGGAAAGCATG-3′.
Co-immunoprecipitation assay. Stimulated BMDM were washed in ice-cold PBS,
and harvested by scraping. The cells were centrifuged at 815 × g for 4 min at 4 °C,
followed by addition of a co-immunoprecipitation (CO-IP) buffer (50 mM HEPES,
pH 8.0, 50 mM NaF, 10 mM Na4P2O7, 50 mM NaCl, 5 mM EDTA, 1 mM
Na3VO4, 0.25% sodium deoxycholate, 1% NP-40 with a protease inhibitor cocktail
(Roche)). The cells were suspended and placed on ice for 30 min. The samples were
then centrifuged at 20,379 × g for 5 min at 4 °C, and the supernatants were saved as
the cell lysates. The prepared cell lysates were incubated with each antibody for 3 h
at 4 °C, followed by addition of protein G-sepharose beads (GE healthcare). After
additional incubation for 1 h at 4 °C, the beads were washed three times with CO-
IP buffer containing a protease inhibitor cocktail and resuspended in Laemmli
buffer. The coimmunoprecipitated proteins were resolved by SDS-polyacrylamide
gel electrophoresis (PAGE), and identiﬁed by western blot analysis. Uncropped
scans of the blots can be found as a Supplementary Figure in the Supplementary
Information (Supplementary Fig. 10).
Antibodies. For the western blot analysis, rabbit polyclonal antibody directed
against Irβ (sc-711, Santa Cruz, 1:2000) and β-actin (A5441, SIGMA, 1:5000) was
purchased from Santa Cruz Biotechnology. Rabbit polyclonal antibodies directed
against Irs1 (06–248, Millipore, 1:2000) and Irs2 (MABS15, Millipore, 1:2000) and a
mouse monoclonal antibody directed against phosphotyrosine (05–321, Millipore,
1:5000) were purchased from Millipore. Rabbit polyclonal antibodies directed
against Akt (9272, Cell Signaling, 1:5000), phospho-Akt (Ser-473) (9271, Cell Sig-
naling, 1:2000), phospho-FoxO1 (Ser-256) (9461, Cell Signaling, 1:1000), STAT6
(9362, Cell Signaling, 1:1000), FoxO1 (2880, Cell Signaling, 1:1000), Lamin B1
(9087, Cell Signaling, 1:2000) and G3PDH (2118, Cell Signaling, 1:2000) were
purchased from Cell Signaling Technology. The rabbit polyclonal antibody directed
against phospho-STAT6 (Tyr641) (06–937, Millipore, 1:1000) was purchased from
Millipore. The antibodies used for the ﬂow cytometry were SiglecF-PE (552126, BD
Biosciences), CD11b-APC-Cy7 (557657, BD Biosciences), F4/80-FITC (11–4801,
eBioscience), CD11c-eFluor405 (48–0114, eBioscience), and CD206-APC (141708,
Biolegend). For the co-immunoprecipitation and EMSA, antibodies against HDAC3
(3949, Cell Signaling, 1:1000) and NCoR1 (5948, Cell Signaling, 1:1000) were used.
Transwell migration assay. Chemotaxis of BMDM was quantiﬁed using the
Cultrex 24 well cell migration assay kit (Trevigen). The BMDM (0.5 × 106 /ml)
were placed in the top chamber and 100 ng/ml of recombinant MCP-1 (R & D
systems) was added at 0.5% FBS/RPMI to the bottom chamber. After incubation
for 4 h at 37 °C, the cells in the bottom chamber were collected by cell dissociation.
The collected cells were read at 520 nm emission and 485 nm excitation.
Proliferation assay. BMDM (0.2 × 105) were seeded in 96-well plates in volumes
of 100 μl/well. After the cells were stimulated with 10 ng/ml of IL-4 for 24 h, BrdU
was added at a ﬁnal concentration of 1 μM. DNA synthesis was assayed by the Cell
Proliferation ELISA, BrdU (Roche Molecular Biochemicals), using a luminometer
(Promega).
STZ plus phlorizin. STZ (Sigma) was freshly suspended in sodium citrate buffer
(pH 4.5). The suspension was injected intraperitoneally (150 mg/kg) on day 0 and
day 5 to 8-week-old C57BL/6 mice that had been denied access to food for 5 h.
Phlorizin (Wako) was dissolved in a solution containing 10% ethanol, 15% DMSO
and 75% saline, and injected subcutaneously (0.4 g/kg) twice daily for 7 days
starting from day 7 after the STZ injection. Peritoneal MΦs were then collected
after injection of thioglycolate solution (Wako).
Blood sample assay. Plasma levels of TG, FFA, T-ch and HDL (Wako Pure
Chemical Industries, Ltd) were assayed by enzymatic methods.
Statistical Analysis. Values are expressed as the mean ± SEM and were analyzed
using the JMP 11 software (SAS Institute). Student’s t test was used to analyze the
statistical signiﬁcances of differences between two groups, and ANOVA to analyze
the statistical signiﬁcances of differences among multiple groups. The Tukey-
Kramer test was used for post hoc analysis. The statistical signiﬁcance level was set
at P ≤ 0.05 in all the tests.
Data availability
The authors declare that all data supporting the ﬁndings of this study are available
within the manuscript and its Supplementary Information ﬁles or are available
from the author upon reasonable request.
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